QPS has bought a majority interest in Qualitix Clinical Research to bolster its clinical trial management services offering.
Qualitix, which will operates as Qualitx-QPS, provides phase I-VI trial management and regulatory services, has offices in Taiwan and China and was spun out from Genovate, which still maintains a minority interest.
The firm also runs a dedicated site management organisation, Unitix, which is focused on accelerating patient recruitment.
QPS said that: “With its strong Asia-Pacific regional network of CRO partners, QPS-Qualitix acts as an attractive launching point from which clients may address the rapidly growing Asian market.”
Vincent Yen, CEO of QPS-Taiwan. "This represents the fourth cross-border acquisition QPS has made in the last six months. Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint."